slc7a6 Antibody

What is SLC7A6 and what cellular function does it perform?

SLC7A6 (also known as Y+LAT2) is a transmembrane protein that functions as an amino acid transporter. It forms a functional heterodimer with SLC3A2 (CD98) and primarily operates as an antiporter at the plasma membrane. This transport system exchanges cationic amino acids such as L-arginine from inside cells for neutral amino acids like L-leucine, L-glutamine, and isoleucine, along with sodium ions .

What types of SLC7A6 antibodies are available for research applications?

Several types of SLC7A6 antibodies are available for research:

Most available antibodies are polyclonal, targeting either the N-terminal or C-terminal regions of the SLC7A6 protein . Some companies offer validated antibodies for specific applications with experimentally confirmed reactivity in human and mouse samples .

What are the recommended applications for SLC7A6 antibodies?

SLC7A6 antibodies have been validated for multiple experimental applications:

For optimal results in immunohistochemistry, antigen retrieval with TE buffer (pH 9.0) is often recommended, although citrate buffer (pH 6.0) may also be used .

What is the optimal protocol for Western blot detection of SLC7A6?

A successful Western blot protocol for SLC7A6 detection typically includes:

• Sample preparation:

  • Lyse cells with RIPA buffer containing protease and phosphatase inhibitors

  • Quantify protein using BCA protein assay

  • Load approximately 30-35 μg of protein per lane

• Electrophoresis conditions:

  • Use SDS-PAGE gels (typically 10-12%)

  • Run at 100-120V until adequate separation

• Transfer and antibody incubation:

  • Transfer to PVDF membrane

  • Block with 5% non-fat milk or BSA for 1 hour

  • Incubate with primary SLC7A6 antibody (1:500-1:1000 dilution) overnight at 4°C

  • Wash with TBST (3-5 times, 5 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody

  • Develop using ECL detection reagent

• Expected results:

  • The predicted molecular weight of SLC7A6 is 57 kDa

  • The observed band is typically 55-58 kDa

How should SLC7A6 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling are crucial for maintaining antibody activity:

• Storage conditions:

  • Short-term (less than 1 month): Store at 4°C

  • Long-term: Store at -20°C

  • Avoid repeated freeze-thaw cycles

• Buffer composition:

  • Most commercial SLC7A6 antibodies are supplied in:

    • PBS (pH 7.2-7.4) with 0.02% sodium azide and 40-50% glycerol

    • Some preparations may include 0.5% BSA for stability

• Handling recommendations:

  • Thaw antibodies completely before use

  • Mix gently by inverting (avoid vortexing)

  • Centrifuge briefly before opening to collect liquid at the bottom of the tube

  • For long-term storage, consider aliquoting to minimize freeze-thaw cycles

How can researchers validate the specificity of SLC7A6 antibodies?

Validation of SLC7A6 antibody specificity should include multiple approaches:

• Positive and negative controls:

  • Positive controls: HUVEC cells and NIH/3T3 cells have confirmed SLC7A6 expression

  • Negative controls: Use tissues/cells known not to express SLC7A6 or use SLC7A6 knockdown/knockout samples

• Molecular weight verification:

  • Confirm that detected bands match the expected molecular weight (55-58 kDa)

  • Be aware that post-translational modifications may slightly alter apparent molecular weight

• Peptide competition assay:

  • Pre-incubate antibody with immunizing peptide

  • If specific, the signal should be blocked or significantly reduced

• Orthogonal methods:

  • Confirm results with multiple antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression data

• Genetic manipulation:

  • Use siRNA knockdown or CRISPR knockout models

  • Should result in reduced or absent signal in Western blots and immunostaining

What are common challenges when using SLC7A6 antibodies and how to overcome them?

Researchers frequently encounter these challenges:

• Non-specific binding:

  • Challenge: Multiple bands in Western blot or background staining in IHC

  • Solutions:

    • Optimize blocking (try 5% BSA instead of milk)

    • Increase antibody dilution (start with 1:1000 for WB)

    • More stringent washing (increase number and duration of washes)

    • Use more specific secondary antibodies

• Weak or absent signal:

  • Challenge: No detection despite confirmed expression

  • Solutions:

    • Verify sample preparation (ensure protein is not degraded)

    • Try different epitope retrieval methods for IHC (compare TE buffer pH 9.0 vs. citrate buffer pH 6.0)

    • Increase protein loading (up to 50 μg)

    • Reduce antibody dilution

    • Extend primary antibody incubation time

• Inconsistent results:

  • Challenge: Variable results between experiments

  • Solutions:

    • Standardize protocols rigorously

    • Use fresh antibody aliquots

    • Maintain consistent sample handling

    • Include loading controls and normalization

How does SLC7A6 alternative splicing impact cancer research?

Recent research has identified significant roles for SLC7A6 alternative splicing in cancer:

• SLC7A6-RI (Retained Intron) in colon cancer:

  • The SLC7A6-RI isoform has been identified as a prognostic marker in colorectal adenocarcinoma (COAD)

  • Higher expression of SLC7A6-RI correlates with better patient survival

  • Experimental knockdown of SLC7A6-RI promotes cancer cell proliferation

• Mechanistic insights:

  • Gene Set Enrichment Analysis (GSEA) revealed that SLC7A6-RI is involved in multiple cellular pathways:

    • PI3K-AKT-mTOR signaling pathway

    • Mitotic spindle organization

    • TNFα signaling via NF-κB

  • Western blot analysis demonstrated increased levels of phosphorylated mTOR and PCNA after SLC7A6-RI knockdown

• In vivo validation:

  • Human colon cancer xenograft studies in nude mice showed that inhibition of the SLC7A6-RI isoform significantly promotes tumor growth

  • After 14 days of siRNA treatment, tumor weight in the si-SLC7A6-RI group was 1.61 times greater than in control groups

This research highlights SLC7A6-RI as a potential therapeutic target in colorectal cancer, suggesting novel treatment strategies targeting its expression or function.

What methodological approaches are needed to study SLC7A6 in relation to amino acid transport mechanisms?

Studying SLC7A6 transport mechanisms requires specialized techniques:

• Amino acid uptake/efflux assays:

  • Use radiolabeled amino acids (e.g., ³H-arginine, ¹⁴C-leucine)

  • Measure exchange kinetics across various conditions

  • Monitor substrate competition to determine specificity

  • Evaluate sodium-dependence by substituting Na⁺ with other ions

• Heterologous expression systems:

  • Express SLC7A6 in Xenopus oocytes or cell lines lacking endogenous transporters

  • Co-express with SLC3A2 (CD98) to form functional heterodimers

  • Use site-directed mutagenesis to identify critical residues for transport

• Real-time transport measurements:

  • Implement fluorescent amino acid analogs

  • Use pH-sensitive dyes to monitor transport-associated pH changes

  • Apply electrophysiological techniques to measure transport currents

• Interaction studies:

  • Co-immunoprecipitation with SLC3A2 (CD98) to confirm complex formation

  • Proximity ligation assays to visualize protein-protein interactions in situ

  • FRET/BRET analyses to study dynamic interactions

• Subcellular localization:

  • Use immunocytochemistry with validated antibodies

  • Implement subcellular fractionation followed by Western blot

  • Apply super-resolution microscopy to precisely locate transporters

How can researchers analyze SLC7A6 isoform expression in different tissue types?

Analyzing SLC7A6 isoform expression requires specialized approaches:

• Isoform-specific PCR detection:

  • Design primers that specifically amplify different splice variants

  • For example, to detect SLC7A6-RI, primers spanning exon-intron junctions are needed

  • Perform RT-PCR followed by gel electrophoresis to visualize distinct isoforms

  • Use quantitative real-time PCR with isoform-specific primers and probes for relative quantification

• RNA sequencing analysis:

  • Implement specialized bioinformatics pipelines for alternative splicing detection

  • Calculate Percent Spliced In (PSI) values to quantify isoform abundance

  • Perform differential splicing analysis between tissue types

  • Validate findings using targeted PCR methods

• Protein-level detection:

  • Develop isoform-specific antibodies targeting unique epitopes

  • Use isoform-specific siRNAs to validate antibody specificity

  • Implement Western blotting with high-resolution gels to separate closely related isoforms

  • Consider mass spectrometry for unbiased protein isoform identification

• Functional characterization:

  • Compare transport properties of different isoforms using uptake assays

  • Assess subcellular localization differences between isoforms

  • Analyze interaction partners specific to each isoform

What is the role of SLC7A6 in cancer metabolism and potential therapeutic implications?

The role of SLC7A6 in cancer metabolism is an emerging research area:

• Amino acid dependency in cancer:

  • Many cancers exhibit altered amino acid metabolism and transport

  • SLC7A6 mediates exchange of essential amino acids needed for protein synthesis and energy production

  • Cancer cells often upregulate amino acid transporters to support increased metabolic demands

• SLC7A6-RI as a tumor suppressor:

  • Higher expression of SLC7A6-RI correlates with better patient survival in colorectal cancer

  • Knockdown of SLC7A6-RI promotes cancer cell proliferation through PI3K-AKT-mTOR pathway activation

  • This suggests that SLC7A6-RI may have tumor-suppressive properties

• Therapeutic strategies:

  • Potential development of synthetic introns based on SLC7A6-RI for targeted elimination of tumor cells

  • Designing small molecules to modulate SLC7A6 transport function

  • Using SLC7A6-RI expression as a prognostic biomarker

  • Combining amino acid transport inhibition with conventional chemotherapy

• Experimental approaches:

  • Implement CRISPR/Cas9 to modulate SLC7A6 isoform expression

  • Screen for small molecules that enhance SLC7A6-RI expression

  • Develop peptides that mimic SLC7A6-RI function

  • Explore combination therapies targeting multiple metabolic pathways

How can researchers effectively use SLC7A6 antibodies in single-cell analysis techniques?

Adapting SLC7A6 antibodies for single-cell analysis requires specific considerations:

• Single-cell immunostaining optimization:

  • Titrate antibody concentration carefully (typically lower than for bulk assays)

  • Validate antibody specificity in single-cell preparations

  • Implement multiplexing with other markers to identify cell types

  • Use tyramide signal amplification for low-abundance targets

• Mass cytometry (CyTOF) approaches:

  • Conjugate SLC7A6 antibodies with rare earth metals

  • Validate metal-conjugated antibodies against fluorescent counterparts

  • Design panels including lineage markers and functional proteins

  • Implement high-dimensional analysis algorithms (tSNE, UMAP)

• Single-cell Western blotting:

  • Adapt standard Western protocols for microfluidic platforms

  • Use higher antibody concentrations due to limited sample amounts

  • Implement careful controls to ensure specificity at single-cell level

  • Consider fixation protocols to preserve protein integrity

• Spatial transcriptomics integration:

  • Combine antibody-based protein detection with in situ RNA analysis

  • Correlate protein expression with mRNA for SLC7A6 isoforms

  • Map spatial distribution of SLC7A6 expression in heterogeneous tissues

  • Analyze co-expression patterns with interacting partners

This emerging field allows researchers to investigate cell-to-cell variability in SLC7A6 expression and function, providing insights into heterogeneous responses within tissues.